argenx’s (ARGX) Overweight Rating Reiterated at Piper Sandler

Piper Sandler restated their overweight rating on shares of argenx (NASDAQ:ARGXFree Report) in a report issued on Monday morning, Benzinga reports. Piper Sandler currently has a $522.00 target price on the stock.

Several other research analysts also recently commented on the stock. Morgan Stanley decreased their target price on shares of argenx from $515.00 to $510.00 and set an overweight rating on the stock in a research note on Tuesday, May 28th. JPMorgan Chase & Co. cut their price target on shares of argenx from $560.00 to $500.00 and set an overweight rating on the stock in a report on Monday, May 13th. Wedbush reiterated an outperform rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. JMP Securities dropped their target price on shares of argenx from $471.00 to $468.00 and set a market outperform rating on the stock in a report on Friday, May 10th. Finally, Wells Fargo & Company boosted their target price on shares of argenx from $472.00 to $478.00 and gave the company an overweight rating in a report on Tuesday, February 20th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $520.68.

Check Out Our Latest Stock Analysis on argenx

argenx Stock Performance

ARGX stock opened at $377.96 on Monday. The company has a market capitalization of $22.46 billion, a PE ratio of -66.78 and a beta of 0.65. argenx has a one year low of $327.73 and a one year high of $550.76. The company’s 50 day moving average price is $374.86 and its two-hundred day moving average price is $388.01.

argenx (NASDAQ:ARGXGet Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The business had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. During the same period last year, the business posted ($0.52) earnings per share. On average, research analysts predict that argenx will post -2.75 EPS for the current year.

Hedge Funds Weigh In On argenx

A number of hedge funds have recently bought and sold shares of ARGX. Lindbrook Capital LLC increased its position in shares of argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after purchasing an additional 37 shares during the last quarter. Wahed Invest LLC increased its position in shares of argenx by 9.6% during the 4th quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares during the last quarter. Daiwa Securities Group Inc. increased its position in shares of argenx by 2.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock valued at $582,000 after purchasing an additional 41 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of argenx by 3.1% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock valued at $543,000 after purchasing an additional 43 shares during the last quarter. Finally, Toronto Dominion Bank increased its position in shares of argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after purchasing an additional 43 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Company Profile

(Get Free Report)

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Featured Articles

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.